– USA, UT – Scientia Vascular, LLC, a commercial-stage medical device company with patented, proprietary, and FDA-approved vascular access technology, recently appointed Rick Randall as executive director to its board. Rick has served as CEO for both private and publicly traded companies such as Target Therapeutics, Innovasive Devices, TranS1 and OMNIlife Science. Mr. Randall brings extensive experience in medical device general management, strategic planning, product/procedure marketing and commercialization.
“Rick brought the first interventional neuro company, Target Therapeutics, public and was key in developing the first neuro technologies. His joining our team reflects the great potential our product lines bring to patients and neuro and peripheral interventionalists worldwide,” said company founder and CEO, John Lippert.
Sales and Marketing Vice President David Rardin stated, “The tremendous response we’ve had clinically is accelerating our product adoption, and Rick’s executive role on our team will help us capture this opportunity.”
“Scientia’s next-generation vascular access technology is perfectly suited to the stringent demands of the rapidly growing interventional stroke treatment market,” Rick Randall commented. “I look forward to joining the Scientia board and management team as they continue to redefine the way the neuro and peripheral vascular system is accessed and treated.”
Rick Randall has over 40 years of experience in the medical device industry, primarily focused on introducing novel, minimally invasive therapeutic products to global markets.
Scientia Vascular develops its own leading-edge neuro and peripheral access technologies, which are patented and form the basis for their proven superior performance.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.